Active substanceRimantadineRimantadine Similar drugsTo uncover Orvirem® syrup inwards d / children Remantadine® capsules inwards Olainfarm, AO Latvia Remantadine® pills inwards EN.S. PHARM, LTD. Russia Remantadine® pills inwards ROSFARM, LLC Russia Rimantadine pills inwards NGO Farmvilar, OOO Russia Rimantadine pills inwards ATOLL, LLC Russia Rimantadine pills inwards MARBIOFARM, OJSC Russia Rimantadine pills inwards TATHIMFARMPREPARATY, JSC Russia Rimantadine pills inwards MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC Russia Rimantadine pills inwards BIOSINTEZ, PAO Russia Rimantadine pills inwards EVROFARM, CJSC Russia Rimantadine pills inwards MOSCOW ENDOCRINE FACTORY, FSUE Russia Rimantadine pills inwards UZOLE-SIBERIAN CHEMICAL PLANT, OJSC Russia Rimantadine pills inwards En.S. Pharmaceuticals, LLC Russia Rimantadine Avecsima pills inwards AVEKSIMA, JSC Russia Rimantadine Aktitab pills inwards OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC Russia Rimantadine Kids syrup inwards d / children PHARMSTANDART-FORESTRY, OJSC Russia Dosage form: & nbspCapsules Composition:Composition of the contents of one capsule:active substance - rimantadine hydrochloride 100.0 mg;Excipients - lactose monohydrate 148.7 mg, potato starch 48.0 mg, stearic acid 3.0 mg, dye sunset yellow sunset [Eurolake Sunset Yellow HS (EllO)] 0.3 mg.The composition of white capsule № 0: titanium dioxide (E 171), gelatin. Description:hard gelatin capsules № 0 of white color. The contents of the capsules are orange powder with a tinge from slightly pink to brownish, with white inclusions. Pharmacotherapeutic group:An antiviral agent. ATX: & nbspJ.05.A.C Cyclic aminesJ.05.A.C.02 Rimantadine Pharmacodynamics:Remantadin ® is active against influenza A virus (especially A2 type).As a weak base, Remantadin® acts by increasing the pH of the endosome, having a membrane of vacuoles that surround the viral particles after they enter the cell. The prevention of acidification in these vacuoles blocks the fusion of the viral envelope with the endosome membrane, thus preventing the transfer of the viral genetic material to the cytoplasm of the cell. Remantadine® also inhibits the release of viral particles from the cell, i.e. interrupts the transcription of the viral genome. Pharmacokinetics:After ingestion Remantadin® is almost completely absorbed in the intestine.Absorption is slow. The connection with plasma proteins is about 40%. The volume of distribution: adults - 17-25 l / kg, children - 289 l / kg. Concentration in nasal secretion is 50% higher than in plasma. The maximum concentration (Сmах) of active substance in blood plasma of a single dose of 100 mg once a day is reached in 6 hours and is 181 ng / ml, at 100 mg twice a day - 416 ng / ml.Metabolised in the liver. The half-life is 24-36 h; 75-85% of the accepted dose is excreted by the kidneys mainly in the form of metabolites, 15% - in unchanged form.In chronic renal failure, the half-life (T1 / 2) increases by a factor of 2. In individuals with kidney failure and in elderly people, it can accumulate in toxic concentrations if the dose is not corrected in proportion to the decrease in creatinine clearance (CC). Indications:Early treatment of influenza A in adults and children older than 14 years. Contraindications:- Acute liver disease,- acute and chronic kidney disease,- thyrotoxicosis,- pregnancy and lactation period,- Children under the age of 14 (for this dosage form),- hypersensitivity to rimantadine or excipients of the drug,- Lactase deficiency, lactose intolerance, glucose-galactose malabsorption. Carefully:Arterial hypertension, epilepsy (including in the anamnesis), atherosclerosis of cerebral vessels, hepatic insufficiency, diseases of the gastrointestinal tract. Pregnancy and lactation:Remantadine® is contraindicated in pregnancy and lactation. Dosing and Administration:Inside, after eating, washed down with water. Capsule can not be chewed.The use of the drug should be started immediately after the appearance of the first symptoms of influenza. The therapeutic effect is more pronounced if the application is started within the first 24-48 hours.Adults and children over 14 years of age on the first day are prescribed 100 mg 3 times a day; in the second and third days of 100 mg 2 times a day; on the fourth and fifth days of 100 mg once a day. On the first day of the disease, the drug can be used once in a dose of 300 mg.Duration of treatment is 5 days. Side effects:Remantadine® is usually well tolerated. Sometimes there are:- from the gastrointestinal tract: dry mouth, nausea, vomiting, loss of appetite, epigastric pain, flatulence;- from the central nervous system: headache, dizziness, insomnia, neurological reactions, impaired concentration, drowsiness, anxiety, increased excitability, fatigue;- Other: Hyperbilirubinemia, allergic reactions (skin rash, itching, hives, etc.). Overdose:Symptoms: excitement, hallucinations, arrhythmia.Treatment: gastric lavage, symptomatic therapy: measures to maintain vital functions. Rimantadine partially excreted in hemodialysis. Interaction:Rimantadine reduces the effectiveness of antiepileptic drugs.Adsorbents, astringents and enveloping agents reduce the absorption of rimantadine. Urinary acidifying agents (acetazolamide, sodium hydrogen carbonate and others) enhance the effectiveness of rimantadine due to a decrease in its secretion by the kidneys.Paracetamol and ascorbic acid reduce the maximum concentration of rimantadine in blood plasma by 11%.Cimetidine reduces the clearance of rimantadine by 18%. Special instructions:With the use of Remantadin ®, there may be an exacerbation of chronic concomitant diseases. In elderly patients with hypertension, the risk of hemorrhagic stroke increases. With a history of epilepsy and ongoing anticonvulsant therapy with Remantidine®, the risk of epilepticseizure. In such cases, Remantadin® is used at a dose of 100 mg per day simultaneously with anticonvulsant therapy.With influenza caused by virus B, Remantadin® has an antitoxic effect.Prophylactic reception is effective at contacts with the sick, with the spread of infection in closed collectives and at a high risk of the disease during the flu epidemic.Perhaps the emergence of drug-resistant viruses. Effect on the ability to drive transp. cf. and fur:Remantadine® does not affect the ability to drive a vehicle, but people with dizziness, headache, or other side effects from the central nervous system should be careful. Form release / dosage:Capsules of 100 mg. Packaging:10 capsules per contour cell packaging made of polyvinylchloride film and aluminum foil.For 1 or 3 contour mesh packages together with the instruction for use are placed in a pack of cardboard. Storage conditions:In a dry, the dark place at a temperature of no higher than 25 0C.Keep out of the reach of children. Shelf life:2 years.Do not use after expiry date. Terms of leave from pharmacies:On prescription Registration number:LP-002369 Date of registration:13.02.2014 The owner of the registration certificate:Olainfarm, AOOlainfarm, AO Latvia Manufacturer: & nbspOLAINFARM, AS Latvia Representation: & nbspOLAINFARM JSC OLAINFARM JSC Latvia Information update date: & nbsp20.09.2015 Illustrated instructions × Illustrated instructions Instructions